U.S. FDA issues 11 observations to formulation unit of Aurobindo Pharma arm in Hyderabad

The U.S. Food and Drug Administration (U.S. FDA) has issued 11 observations to the formulation manufacturing installation of Aurobindo Pharma’s subsidiary Eugia Pharma Specialities successful Hyderabad.

The observations were issued connected decision of an inspection, by the U.S. FDA, of the installation (Unit-III) from January 27 to February 6. The The observations are procedural successful quality and volition beryllium responded to wrong the stipulated time, Aurobindo Pharma said successful a filing connected Friday.